


NanoBioAnalytical tools for blood-derived extracellular vesicles characterization

Celine Elie-Caille

FEMTO-ST Institute, Micro Nano Sciences and Systems (MN2S) department / BioMicroDevices group, Besançon (France)


Blood EV content : multiple origins and functions

In Cancer




From Goubran (Burnouf T.) et al, Trans Aph 2015

In thrombosis



From Gustafson et al, 2017

In inflammation, etc...




From Barteneva et al, 2017

- EVs produced by all cells
- EVs = potential circulating biomarker candidates
- 10^4 to 10^6 EVs/ml in blood : High concentration



**Blood circulating EVs :
at the height
of the cell-cell communication**

Limits surrounded EVs analytical methods



In solution : difficult, even impossible to have concentration, size and phenotype, at once



Our NanoBioAnalytical platform




EVs phenotyping & spatialization on microarrays

Advantages of NBA:


- home-made biochips
- on original biological samples
- label-free methods




EVs viewing, sizing and counting






EVs proteomic profiles




The gold biochip: the corner stone of NBA



Array Spotting





Modular biointerface:
1 to 96 spots
Surface coverage:
Until 15 000 Ab/ μm^2




Phase contrast image of the biochip in SPRI-Plex II (Horiba)

Calibration of NBA: nanoparticles covering 50 nm to 1 μm

- VP1 capsid protein of norovirus
- 50 nm
- Anti-CP50



- Biofunctionalized bead
- 920 nm
- Anti-CP920





CP50 particles :

Specific & stable CP50 capture
Dynamic range for CP50 :
 $2,5 \times 10^9 - 2 \times 10^{11}$ CP50/mL

CP920 particles :

Specific & stable CP920 capture
Dynamic range for CP920 :
 $3,25 \times 10^7 - 3,25 \times 10^8$ CP920/mL

NBA for EVs biodetection, sizing and morphology



EVs used : platelet-derived EVs



➤ NBA efficient to dose, select, spatialize, evaluate size and morphology of EVs subsets

Application of NBA to a biological model: Platelet-derived EVs effect on monocytes

Collaboration : T. Burnouf, Taiwan




Objective : understand the **pro-inflammatory and pro-thrombotic « role »** of EVs from plasma or platelet concentrates in transfused patients



T-PEVs induce aggregation of THP1...

Neutrophil aggregation and extracellular traps (NETs)


stimuli




Neutrophils

neutrophils release granule proteins and chromatin to form an extracellular fibril matrix known as NETs

Pathogen trapping & killing



NETs: paradoxical physiological impact ?




Hypothesis:

Thrombogenic risks of plasma for transfusion are mediated by PEVs through:






- direct thrombin generation
- and neutrophil activation

Neutrophil aggregation and extracellular traps (NETs)

N-PEVs on neutrophils



T-PEVs on neutrophils





DNA (blue), histone H1 (green), and MPO (red)

→ T-PEVs induce aggregation of neutrophil aggregation and NETs formation...

T-PEVs effect on monocytes : concentration ?? size ?? composition???


Differential EVs subsets capture on the chip




➤ T-PEV : capture +++ on αCD41 and αCD62P

	Concentration (EVs/mL)	
	Qnano	FC
N-PEVs	3,7x10 ¹²	2,1x10 ¹⁰
T-PEVs	1,3x10 ¹¹	6,8x10 ⁹

...Not due to the EVs concentration




...Not due to the EVs size ...



Proteomics of EVs subsets captured on the chip (1/3)


MS workflow in detail for NBA



Proteomics of EVs subsets captured on the chip (2/3)

EVs proteomics « on arrays »



“On array” MS optimization



Protein Set	Description	T-PEVs		N-PEVs	
		Score T-PMP	Peptides T-PMP	Score N-PMP	Peptides N-PMP
Q9Y490	Talin-1	3232,74	49	3943,33	61
P21333	Filamin-A	2805,99	47	3778,84	62
AOA024QZN4	Vinculin, isoform CRA_c	1275,97	23	1157,94	24
P08514	Integrin alpha-IIb	1233,54	17	1653,09	25
P60709	Actin, cytoplasmic 1	1076,79	19	1345,02	25
AOA0A0MRJ7	Coagulation factor V	259,97	5	945,11	17
F6KPG5	Albumin (Fragment)	1031,38	17	608,76	10
AOA024R882	Stomatin, isoform CRA_a	808,04	10	921,68	12
E7EPG1	Multimerin-1	45,33	1	690,01	13
L7UUZ7	Integrin beta	611,35	9	604,56	9
P11142	Heat shock cognate 71 kDa protein	609,84	9	666,08	12
AOA024R1N1	Myosin, heavy polypeptide 9, non-muscle	576,45	10	550,12	8
P02671	Fibrinogen alpha chain	493,98	11	133,44	3
AOA0A0MS51	Gelsolin	489,27	9	823,74	13
AOA024R3E3	Apolipoprotein A-I, isoform CRA_a	463,22	9	300,03	5
A8K486	Peptidyl-prolyl cis-trans isomerase	457,41	8	355,44	6
AOA024R694	Actinin, alpha 1, isoform CRA_a	428,23	8	327,95	7
AOA024RB87	RAP1B, member of RAS oncogene family	390,9	5	527,1	7
P11021	78 kDa glucose-regulated protein	390,21	7	230,05	4
P04406	Glyceraldehyde-3-phosphate dehydrogenase	367,78	6	542,4	10
P13224	Platelet glycoprotein Ib beta chain	350,35	6	367,7	7
B4DE78	cDNA FU52141, highly similar to 14-3-3 protein gamma	344,31	7	332,17	6
Q86UX7	Fermitin family homolog 3	341,67	5	409,09	6
AOA024R5Z9	Pyruvate kinase	340,44	6	353,76	6
D0PNI1	Epididymis luminal protein 4	339,64	5	463,93	7
.....
.....

~ 200 proteins identified from ~ 500 ng of captured EV and several differential proteins ...

Proteomics of EVs subsets captured on the chip (3/3)




T-PEV : capture +++
 on aCD41 and aCD62P...
 Due to protein expression
 level ? Yes !

NBA: an upgradeable platform

**BOURSE REGION
2017-2020**





*Inserts for cell
coculture*



**ANR MADNESS
with LAAS**

Toulouse



Cut off = 700 nm

*Bourse Ministère
2013-2017: S. Obeid*

Platelet derived EVs

- *TMU, Taiwan*
- *HUG*
- *INSERM U1098*

Plasma EVs in cancer

- *Marseille (R. Tomasini)*
- *Dijon (C. Garrido)*
- *Besançon (C. Borg)*

**Acoustofluidic sorting
(Oct-Dec 2018)**

A. Khelif (FEMTO-ST)



Acknowledgments

FEMTO-ST Institute & CLIPP

S. Obeid
K. Maximova
W. Boireau
A. Rouleau
K. Maximova
G. Lucchi, P. Maes

Collaborators


T. Burnouf
A-M Gué
T. Lecompte
P. Saas

Fundings


FEDER « MIMEDI » 2018
ANR 2017 « MADNESS »
Région Franche Comté (2017)
CNRS : Défi instrum. aux limites 2017



« EV group » in BioMicroDevice Team



May 2018, at FEMTO-ST Institute



THANK YOU !